Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kairos Pharma, Ltd. ( (KAPA) ) has provided an update.
On July 15, 2025, Kairos Pharma, Ltd. announced positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer. The interim safety analysis showed that the drug was well tolerated with no dose-limiting toxicities or unexpected adverse events, and no Grade 3 or 4 toxicities were observed. This development supports the continued advancement of ENV-105, addressing the unmet need for effective treatments in a patient population with limited options. The trial aims to enroll 100 patients and is currently accruing participants at several medical centers, with interim efficacy data expected in September 2025. Kairos Pharma plans to engage with regulatory agencies for a potential Phase 3 study based on emerging data.
The most recent analyst rating on (KAPA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.
More about Kairos Pharma, Ltd.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapeutics. The company aims to advance a pipeline of targeted therapies for cancer patients with high unmet medical needs, providing safe and effective solutions to improve the efficacy of existing standard care for challenging forms of cancer.
Average Trading Volume: 901,160
Technical Sentiment Signal: Strong Sell
Find detailed analytics on KAPA stock on TipRanks’ Stock Analysis page.